Anavex Life Sciences (AVXL) Enterprise Value (2010 - 2025)
Anavex Life Sciences (AVXL) posted Enterprise Value of -$131.7 million for Q4 2025, down 28.44% sequentially from -$102.6 million in Q3 2025, and down 9.09% YoY from -$144.9 million in Q4 2024.
Anavex Life Sciences (AVXL) Enterprise Value (2010 - 2025) Analysis & Trends
Anavex Life Sciences has reported Enterprise Value for 16 years, with the latest figure at -$131.7 million in Q4 2025.
- Quarterly Enterprise Value fell 9.09% year-over-year to -$131.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$131.7 million (down 9.09% YoY) and the FY2025 annual result came in at -$102.6 million, up 22.4% from the prior year.
- Enterprise Value eased to -$131.7 million in Q4 2025 per AVXL's latest filing, from -$102.6 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$75.9 million in Q1 2021 and troughed at -$157.6 million in Q2 2021.
- A 5-year average of -$136.1 million and a median of -$143.7 million in 2022 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2021 and 2025: Enterprise Value sank 470.47% in 2021, then climbed 27.09% in 2025.
- Over 5 years, Enterprise Value stood at -$151.1 million in 2021, then increased by 4.98% to -$143.6 million in 2022, then fell by 0.1% to -$143.8 million in 2023, then grew by 15.99% to -$120.8 million in 2024, then declined by 9.09% to -$131.7 million in 2025.
- According to Business Quant data, Enterprise Value over the past three periods registered -$131.7 million, -$102.6 million, and -$101.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Anavex Life Sciences | 298.40 Mn | 166.65 Mn | - | -131.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -131.75 Mn |
| Sep 30, 2025 | -102.58 Mn |
| Jun 30, 2025 | -101.16 Mn |
| Mar 31, 2025 | -115.77 Mn |
| Dec 31, 2024 | -120.78 Mn |
| Sep 30, 2024 | -132.19 Mn |
| Jun 30, 2024 | -138.76 Mn |
| Mar 31, 2024 | -139.39 Mn |
| Dec 31, 2023 | -143.77 Mn |
| Sep 30, 2023 | -151.02 Mn |
| Jun 30, 2023 | -154.82 Mn |
| Mar 31, 2023 | -153.47 Mn |
| Dec 31, 2022 | -143.62 Mn |
| Sep 30, 2022 | -149.16 Mn |
| Jun 30, 2022 | -153.20 Mn |
| Mar 31, 2022 | -153.34 Mn |
| Dec 31, 2021 | -151.15 Mn |
| Sep 30, 2021 | -152.11 Mn |
| Jun 30, 2021 | -157.56 Mn |
| Mar 31, 2021 | -75.86 Mn |